PMC:7408073 / 109177-112683 JSONTXT

Annnotations TAB JSON ListView MergeView

LitCovid-PD-FMA-UBERON

Id Subject Object Predicate Lexical cue fma_id
T34 160-164 Body_part denotes lung http://purl.org/sig/ont/fma/fma7195
T35 958-964 Body_part denotes plasma http://purl.org/sig/ont/fma/fma62970
T36 1746-1751 Body_part denotes blood http://purl.org/sig/ont/fma/fma9670
T37 1762-1772 Body_part denotes eosinophil http://purl.org/sig/ont/fma/fma62861
T38 1930-1946 Body_part denotes epithelial cells http://purl.org/sig/ont/fma/fma66768
T39 1941-1946 Body_part denotes cells http://purl.org/sig/ont/fma/fma68646

LitCovid-PD-UBERON

Id Subject Object Predicate Lexical cue uberon_id
T225 160-164 Body_part denotes lung http://purl.obolibrary.org/obo/UBERON_0002048
T226 1746-1751 Body_part denotes blood http://purl.obolibrary.org/obo/UBERON_0000178
T227 1813-1816 Body_part denotes RAS http://purl.obolibrary.org/obo/UBERON_0018229
T228 2531-2534 Body_part denotes RAS http://purl.obolibrary.org/obo/UBERON_0018229
T229 3008-3011 Body_part denotes RAS http://purl.obolibrary.org/obo/UBERON_0018229

LitCovid-PubTator

Id Subject Object Predicate Lexical cue tao:has_database_id
3701 234-238 Gene denotes AT1R Gene:185
3702 247-251 Gene denotes AT2R Gene:24182
3703 242-246 Gene denotes MasR Gene:116511
3704 379-387 Species denotes patients Tax:9606
3705 109-120 Disease denotes dysfunction MESH:D009461
3706 140-159 Disease denotes cardiac dysfunction MESH:D006331
3707 177-187 Disease denotes thrombosis MESH:D013927
3708 342-353 Disease denotes dysfunction MESH:D009461
3709 389-397 Disease denotes COVID-19 MESH:C000657245
3733 1014-1021 Gene denotes albumin Gene:213
3734 1023-1028 Gene denotes IL-10 Gene:3586
3735 1030-1038 Gene denotes Ang (1–9 Gene:284
3736 1052-1060 Gene denotes Ang (1–5 Gene:284
3737 1069-1079 Gene denotes bradykinin Gene:3827
3738 1138-1141 Gene denotes ACE Gene:59272
3739 1149-1153 Gene denotes ACE2 Gene:59272
3740 1233-1236 Gene denotes ACE Gene:59272
3741 1241-1245 Gene denotes ACE2 Gene:59272
3742 1980-1984 Gene denotes ACE2 Gene:59272
3743 1041-1049 Gene denotes Ang (1–7 Gene:284
3744 992-999 Gene denotes albumin Gene:213
3745 1326-1334 Species denotes patients Tax:9606
3746 1477-1485 Species denotes patients Tax:9606
3747 1685-1692 Species denotes patient Tax:9606
3748 972-976 Chemical denotes Zn2+
3749 734-746 Disease denotes dysfunctions MESH:D009461
3750 883-891 Disease denotes COVID-19 MESH:C000657245
3751 1317-1325 Disease denotes COVID-19 MESH:C000657245
3752 1351-1379 Disease denotes eosinopaenia and hypotension MESH:D007022
3753 1847-1859 Disease denotes inflammation MESH:D007249
3754 2060-2080 Disease denotes SARS-CoV-2 infection MESH:C000657245
3755 2153-2161 Disease denotes COVID-19 MESH:C000657245
3762 2626-2630 Gene denotes ACE2 Gene:59272
3763 2695-2699 Gene denotes ACE2 Gene:59272
3764 2827-2835 Species denotes patients Tax:9606
3765 2384-2392 Disease denotes COVID-19 MESH:C000657245
3766 2465-2473 Disease denotes COVID-19 MESH:C000657245
3767 3122-3129 Disease denotes failure MESH:D006333

LitCovid-PD-MONDO

Id Subject Object Predicate Lexical cue mondo_id
T595 177-187 Disease denotes thrombosis http://purl.obolibrary.org/obo/MONDO_0000831
T596 389-397 Disease denotes COVID-19 http://purl.obolibrary.org/obo/MONDO_0100096
T597 883-891 Disease denotes COVID-19 http://purl.obolibrary.org/obo/MONDO_0100096
T598 1317-1325 Disease denotes COVID-19 http://purl.obolibrary.org/obo/MONDO_0100096
T599 1368-1379 Disease denotes hypotension http://purl.obolibrary.org/obo/MONDO_0005468
T600 1847-1859 Disease denotes inflammation http://purl.obolibrary.org/obo/MONDO_0021166
T601 2060-2068 Disease denotes SARS-CoV http://purl.obolibrary.org/obo/MONDO_0005091
T602 2060-2064 Disease denotes SARS http://purl.obolibrary.org/obo/MONDO_0005091
T603 2071-2080 Disease denotes infection http://purl.obolibrary.org/obo/MONDO_0005550
T604 2153-2161 Disease denotes COVID-19 http://purl.obolibrary.org/obo/MONDO_0100096
T605 2222-2225 Disease denotes flu http://purl.obolibrary.org/obo/MONDO_0005812
T606 2384-2392 Disease denotes COVID-19 http://purl.obolibrary.org/obo/MONDO_0100096
T607 2465-2473 Disease denotes COVID-19 http://purl.obolibrary.org/obo/MONDO_0100096

LitCovid-PD-CLO

Id Subject Object Predicate Lexical cue
T94 160-164 http://purl.obolibrary.org/obo/UBERON_0002048 denotes lung
T95 160-164 http://www.ebi.ac.uk/efo/EFO_0000934 denotes lung
T96 213-223 http://purl.obolibrary.org/obo/CLO_0001658 denotes activation
T97 401-402 http://purl.obolibrary.org/obo/CLO_0001020 denotes a
T98 584-585 http://purl.obolibrary.org/obo/CLO_0001020 denotes a
T99 608-609 http://purl.obolibrary.org/obo/CLO_0001020 denotes a
T100 958-964 http://purl.obolibrary.org/obo/UBERON_0001969 denotes plasma
T101 1164-1172 http://purl.obolibrary.org/obo/CLO_0001658 denotes activity
T102 1246-1254 http://purl.obolibrary.org/obo/CLO_0001658 denotes activity
T103 1746-1751 http://purl.obolibrary.org/obo/UBERON_0000178 denotes blood
T104 1746-1751 http://www.ebi.ac.uk/efo/EFO_0000296 denotes blood
T105 1817-1825 http://purl.obolibrary.org/obo/PR_000018263 denotes peptides
T106 1866-1869 http://purl.obolibrary.org/obo/PR_000001343 denotes aim
T107 1930-1940 http://purl.obolibrary.org/obo/CL_0000066 denotes epithelial
T108 1941-1946 http://purl.obolibrary.org/obo/GO_0005623 denotes cells
T109 2213-2214 http://purl.obolibrary.org/obo/CLO_0001020 denotes a
T110 2227-2228 http://purl.obolibrary.org/obo/CLO_0001020 denotes a
T111 2433-2434 http://purl.obolibrary.org/obo/CLO_0001020 denotes a
T112 2646-2649 http://purl.obolibrary.org/obo/CLO_0051582 denotes has
T113 2679-2687 http://purl.obolibrary.org/obo/CLO_0001658 denotes activity
T114 2856-2857 http://purl.obolibrary.org/obo/CLO_0001020 denotes a
T115 3041-3043 http://purl.obolibrary.org/obo/CLO_0050475 denotes my
T116 3096-3097 http://purl.obolibrary.org/obo/CLO_0001020 denotes a
T117 3120-3121 http://purl.obolibrary.org/obo/CLO_0001020 denotes a

LitCovid-PD-CHEBI

Id Subject Object Predicate Lexical cue chebi_id
T62900 972-975 Chemical denotes Zn2 http://purl.obolibrary.org/obo/CHEBI_37256
T20847 987-991 Chemical denotes zinc http://purl.obolibrary.org/obo/CHEBI_27363|http://purl.obolibrary.org/obo/CHEBI_30185
T4937 1023-1025 Chemical denotes IL http://purl.obolibrary.org/obo/CHEBI_63895|http://purl.obolibrary.org/obo/CHEBI_74072
T2350 1069-1079 Chemical denotes bradykinin http://purl.obolibrary.org/obo/CHEBI_3165
T24872 1813-1816 Chemical denotes RAS http://purl.obolibrary.org/obo/CHEBI_63620
T53946 1817-1825 Chemical denotes peptides http://purl.obolibrary.org/obo/CHEBI_16670
T12617 2531-2534 Chemical denotes RAS http://purl.obolibrary.org/obo/CHEBI_63620
T93364 2535-2545 Chemical denotes inhibitors http://purl.obolibrary.org/obo/CHEBI_35222
T25023 2599-2603 Chemical denotes drug http://purl.obolibrary.org/obo/CHEBI_23888
T91571 2626-2640 Chemical denotes ACE2 inhibitor http://purl.obolibrary.org/obo/CHEBI_147289
T70701 2631-2640 Chemical denotes inhibitor http://purl.obolibrary.org/obo/CHEBI_35222
T14447 2725-2729 Chemical denotes drug http://purl.obolibrary.org/obo/CHEBI_23888
T92382 2943-2947 Chemical denotes drug http://purl.obolibrary.org/obo/CHEBI_23888
T52971 3008-3011 Chemical denotes RAS http://purl.obolibrary.org/obo/CHEBI_63620

LitCovid-PD-GO-BP

Id Subject Object Predicate Lexical cue
T11 1847-1859 http://purl.obolibrary.org/obo/GO_0006954 denotes inflammation

LitCovid-sentences

Id Subject Object Predicate Lexical cue
T542 0-4 Sentence denotes 8.4.
T543 5-33 Sentence denotes Safety and Efficacy Concerns
T544 34-418 Sentence denotes Unfortunately, diseases of different aetiologies may present similar final dysfunction/alterations (e.g., cardiac dysfunction/lung alterations/thrombosis are induced by excessive activation of either AT1R or MasR/AT2R pathways, see Figure 1), while diseases with same aetiologies may present different final dysfunction/alterations depending on patients (COVID-19 is a clear example).
T545 419-631 Sentence denotes This confounding aspect of diseases can lead to erroneous interpretations, and only defining the correct and early molecular origin of diseases is possible to reach a successful outcome if a therapy is available.
T546 632-824 Sentence denotes In order to decide who to treat, and when to start treatment, it is important to define the entity of dysfunctions, probability of treatment success and probability to develop adverse effects.
T547 825-938 Sentence denotes To promptly intervene in order to prevent severe forms of COVID-19, we need early markers of disease progression.
T548 939-1335 Sentence denotes To this regard, if plasma (free) Zn2+ (or total zinc/albumin molar ratio), albumin, IL-10, Ang (1–9), Ang (1–7), Ang (1–5) and/or bradykinin (1–7) will be proven to be reliable surrogate markers for ACE and/or ACE2 enzymatic activity in vivo, they could be exploited, together with circulating ACE and ACE2 activity evaluation, in order to decide who and when to start treating COVID-19 patients.
T549 1336-1434 Sentence denotes Alternatively, eosinopaenia and hypotension may be also exploited as signs of disease progression.
T550 1435-1861 Sentence denotes In any case, since the conditions of some patients can be critical, it is highly recommended to administer the minimal effective dose in order to reduce possible side effects, starting with low and increasing doses, while at the same time monitoring patient status and early signs of disease progression (e.g., blood pressure, eosinophil counts, molecular concentrations of the RAS peptides and other markers of inflammation).
T551 1862-2262 Sentence denotes The aim of the project was not necessarily to stop viral entry (the epithelial cells take already care of it shedding ACE2) but to block positive feedback loops that follow the cellular response to SARS-CoV-2 infection, which are likely the main cause of the severe symptoms associated with COVID-19, doing so, the disease might hopefully become like a simple flu, a spontaneously eradicable disease.
T552 2263-2393 Sentence denotes At the moment, I am alone in proposing these new and non-conventional therapeutic approaches that may or may not work on COVID-19.
T553 2394-2579 Sentence denotes In doing so, I have not only described a rationale/strategy to counter COVID-19, but also provided practical information to optimize the RAS inhibitors based on known experimental data.
T554 2580-2769 Sentence denotes Before any in vivo drug administration (e.g., ACE2 inhibitor), it has to be checked the biological activity (e.g., ACE2) that is affected by the drug, considering the possible side effects.
T555 2770-2948 Sentence denotes However, this is not always the case and, in some cases, patients are treated without a careful evaluation of the biological parameter that is modulated by the administered drug.
T556 2949-3161 Sentence denotes In this regard, I have tried to address all aspects of the RAS inhibition in detail because my main concern is that the use of these approaches in a wrong way may lead to a failure or even to deleterious effects.
T557 3162-3405 Sentence denotes That is why I have meticulously described all the steps before possible administration and provided the guideline suggestions and specific recommendations in order to increase the probability of success and to minimize the deleterious effects.
T558 3406-3506 Sentence denotes The readers are, however, expected and encouraged to debate and make their own optimized guidelines.

LitCovid-PD-HP

Id Subject Object Predicate Lexical cue hp_id
T173 1368-1379 Phenotype denotes hypotension http://purl.obolibrary.org/obo/HP_0002615